Analyst Price Targets — KLRS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 14, 2026 10:55 am | — | Wedbush | $17.00 | $4.83 | TheFly | Kalaris Therapeutics initiated with an Outperform at Wedbush |
| April 16, 2026 8:54 am | — | Morgan Stanley | $14.00 | $5.87 | TheFly | Kalaris Therapeutics initiated with an Overweight at Morgan Stanley |
| March 9, 2026 2:57 pm | Chris Raymond | Raymond James | $23.00 | $9.51 | StreetInsider | Raymond James Reiterates Strong Buy Rating on Kalaris (KLRS) |
| December 23, 2025 9:31 am | — | Chardan Capital | $19.00 | $10.06 | TheFly | Kalaris Therapeutics initiated with a Buy at Chardan |
| July 23, 2025 8:52 am | Biren Amin | Piper Sandler | $3.00 | $2.57 | TheFly | Kalaris Therapeutics assumed with a Neutral at Piper Sandler |
Latest News for KLRS
Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts
Highly experienced biotechnology executive and board member will assist Kalaris in achieving its next phase of growth Highly experienced biotechnology executive and board member will assist Kalaris in achieving its next phase of growth
BERKELEY HEIGHTS, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced an upcoming presentation of Phase 1a data at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting.
BERKELEY HEIGHTS, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, will present Phase 1a clinical data for its lead asset, TH103, at Clinical Trials at the Summit (CTS) 2026. The presentation will feature single ascending dose…
Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027 Planned Phase 3 clinical trials remain on track for 2027 year-end initiation $104.9 million in cash, cash equivalents and marketable securities as of March 31, 2026 is expected to fund operations into the fourth quarter of 2027 and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KLRS.
U.S. House Trading
No House trades found for KLRS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.